Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Cutaneous T Cell Lymphomas
NCT05879458Phase 2Terminated
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ritlecitinib tosilate in cutaneous T-cell lymphoma (CTCL), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Modified Severity Weighted Assessment Tool at Week 24. Started May 2023; status: terminated.
02
Drugs
ritlecitinib tosilate
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT05879458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879458.